EP3890731A4 - Composés pour le traitement d'une infection à arénavirus - Google Patents
Composés pour le traitement d'une infection à arénavirus Download PDFInfo
- Publication number
- EP3890731A4 EP3890731A4 EP19892030.8A EP19892030A EP3890731A4 EP 3890731 A4 EP3890731 A4 EP 3890731A4 EP 19892030 A EP19892030 A EP 19892030A EP 3890731 A4 EP3890731 A4 EP 3890731A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compounds
- treatment
- arenavirus infection
- arenavirus
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000005989 Arenaviridae Infections Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862776390P | 2018-12-06 | 2018-12-06 | |
PCT/US2019/064223 WO2020117794A1 (fr) | 2018-12-06 | 2019-12-03 | Composés pour le traitement d'une infection à arénavirus |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3890731A1 EP3890731A1 (fr) | 2021-10-13 |
EP3890731A4 true EP3890731A4 (fr) | 2022-08-17 |
Family
ID=70975517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19892030.8A Pending EP3890731A4 (fr) | 2018-12-06 | 2019-12-03 | Composés pour le traitement d'une infection à arénavirus |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3890731A4 (fr) |
JP (1) | JP2022509763A (fr) |
KR (1) | KR20210106997A (fr) |
CN (1) | CN113329750A (fr) |
AR (1) | AR117228A1 (fr) |
AU (1) | AU2019393784A1 (fr) |
BR (1) | BR112021010909A2 (fr) |
CA (1) | CA3118765A1 (fr) |
EA (1) | EA202191001A1 (fr) |
MX (1) | MX2021005234A (fr) |
WO (1) | WO2020117794A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995026325A2 (fr) * | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Potentialisation de medicaments par deuteration_______________ |
WO2012065297A1 (fr) * | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-aryl-6-aryl-[1,2,4]triazolo[4,3-a]pyridines en tant qu'inhibiteurs de la prolifération cellulaire et leur utilisation |
WO2018013430A2 (fr) * | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Composés hétérocycliques pour le traitement d'une infection à arenavirus |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9498470B2 (en) * | 2012-02-17 | 2016-11-22 | Kineta Four, LLC | Antiviral drugs for treatment of arenavirus infection |
-
2019
- 2019-12-02 AR ARP190103517A patent/AR117228A1/es unknown
- 2019-12-03 CN CN201980080594.2A patent/CN113329750A/zh active Pending
- 2019-12-03 JP JP2021525159A patent/JP2022509763A/ja active Pending
- 2019-12-03 AU AU2019393784A patent/AU2019393784A1/en active Pending
- 2019-12-03 CA CA3118765A patent/CA3118765A1/fr active Pending
- 2019-12-03 BR BR112021010909-9A patent/BR112021010909A2/pt unknown
- 2019-12-03 EP EP19892030.8A patent/EP3890731A4/fr active Pending
- 2019-12-03 WO PCT/US2019/064223 patent/WO2020117794A1/fr unknown
- 2019-12-03 KR KR1020217017726A patent/KR20210106997A/ko unknown
- 2019-12-03 EA EA202191001A patent/EA202191001A1/ru unknown
- 2019-12-03 MX MX2021005234A patent/MX2021005234A/es unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995026325A2 (fr) * | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Potentialisation de medicaments par deuteration_______________ |
WO2012065297A1 (fr) * | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-aryl-6-aryl-[1,2,4]triazolo[4,3-a]pyridines en tant qu'inhibiteurs de la prolifération cellulaire et leur utilisation |
WO2018013430A2 (fr) * | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Composés hétérocycliques pour le traitement d'une infection à arenavirus |
Non-Patent Citations (3)
Title |
---|
O'DRISCOLL: "Heavyweight drugs", CHEMISTRY & INDUSTRY, 9 March 2009 (2009-03-09), pages 24 - 26, XP002636700, ISSN: 0009-3068 * |
PLEWE ET AL.: "Discovery of a novel highly potent broad-spectrum heterocyclic chemical series of arenavirus cell entry inhibitors", BIOORG. MED. CHEM. LETT., vol. 41, 5 May 2021 (2021-05-05), pages 1 - 9, XP086566088, ISSN: 0960-894X, [retrieved on 20210505], DOI: 10.1016/J.BMCL.2021.127983 * |
See also references of WO2020117794A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA3118765A1 (fr) | 2020-06-11 |
KR20210106997A (ko) | 2021-08-31 |
JP2022509763A (ja) | 2022-01-24 |
CN113329750A (zh) | 2021-08-31 |
EP3890731A1 (fr) | 2021-10-13 |
AU2019393784A1 (en) | 2021-05-27 |
MX2021005234A (es) | 2021-08-11 |
WO2020117794A1 (fr) | 2020-06-11 |
AR117228A1 (es) | 2021-07-21 |
EA202191001A1 (ru) | 2021-08-16 |
BR112021010909A2 (pt) | 2021-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3781564A4 (fr) | Composés pour le traitement d'un cancer | |
EP3490987A4 (fr) | Nouveaux agents thérapeutiques pour le traitement de l'infection par hbv. | |
EP3823568A4 (fr) | Traitement chirurgical du glaucome | |
EP3935050A4 (fr) | Composés hétérocycliques pour traitement médical | |
EP3790867A4 (fr) | Inhibiteurs de kdm1a pour le traitement d'une maladie | |
EP3790563A4 (fr) | Compositions permettant le traitement d'affections cutanées | |
EP3893883A4 (fr) | Méthodes pour le traitement de la dépression | |
EP3784260A4 (fr) | Compositions pour le traitement d'affections cutanées | |
IL276482A (en) | Compounds for pain management | |
EP3883554A4 (fr) | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance | |
EP3405183A4 (fr) | Dérivés d'adamatane pour le traitement d'une infection à filovirus | |
EP3866601A4 (fr) | Organosilanes pour le traitement d'infections | |
EP3877382A4 (fr) | Nouveaux composés pour le traitement de maladies respiratoires | |
EP3773659A4 (fr) | Méthodes de traitement d'une infection par le virus de l'hépatite b (hbv) | |
EP3813872A4 (fr) | Compositions pour le traitement d'affections cutanées | |
EP3619204A4 (fr) | Composés pour traiter des maladies respiratoires | |
EP4121403A4 (fr) | Composés nitro-aminoadamantane pour le traitement d'infections par le bêtacoronavirus | |
EP3852744A4 (fr) | Thérapie combinée pour le traitement du mélanome de la choroïde | |
EP3846820A4 (fr) | Composés sulfamide cycliques pour le traitement du vhb | |
EP3448377A4 (fr) | Méthodes pour le traitement d'une infection | |
EP4021858A4 (fr) | Traitement d'azoles | |
EP4027984A4 (fr) | Polythérapie pour le traitement de migraines | |
EP3934632A4 (fr) | Eskétamine pour le traitement de la dépression | |
EP3873528A4 (fr) | Traitement de rasopathie | |
EP3890731A4 (fr) | Composés pour le traitement d'une infection à arénavirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210604 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031418400 Ipc: C07D0249160000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220719 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/4184 20060101ALI20220713BHEP Ipc: A61P 31/14 20060101ALI20220713BHEP Ipc: C07D 487/04 20060101ALI20220713BHEP Ipc: C07D 471/04 20060101ALI20220713BHEP Ipc: C07D 249/18 20060101ALI20220713BHEP Ipc: C07D 249/16 20060101AFI20220713BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231208 |